Personnel programs and scientific research tasks involved
2016/08-2019/06. The person in charge of The Preliminary Study of the Effects of Denervation on the Occurrence and Progression of Pancreatic Cancer, a project of Jiangsu Provincial Natural Science Foundation;
2014/01-2016/12. The person in charge of The Experimental Study of Regional Injection of Type A Creotoxin for the Treatment of Pancreatic Cancer, a project of Jiangsu “Six Talented Personnel Summit”;
2013/01-2016/12. Participated in How Chronic Pancreatitis is Mediated by the Epithelial-Mesenchymal of Pancreatic Stellate Cell, a project of Natural Science Foundation of China;
2012/06-2017/01. Participated in the subsidiary subject of the Translational Medicine Study of the Early Diagnosis and Comprehensive Treatment of Pancreatic Cancer, an Industry Project of the Ministry of Health;
2012/01-2015/12. Participated in The Study of the Mechanism of the High Tolerance of the Bile Duct Cells of Rats Suffered from Liver Cirrhosis towards Ischemia, a project of Natural Science Foundation of China;2010/01-2012/12. Participated in the Study of the Mechanism of How the High Expression Galectin-1 of Pancreatic Stellate Cell Promotes Pancreatic Cancer Immunosuppression, a project of Natural Science Foundation of China;
2010/01-2012/12. Participated in the Study of the New Methods that Separates and Identifies the Stem Cells of Pancreatic Cancer and Relevant Biological Characteristics, a project of Natural Science Foundation of China;
2008/09-2013/01. Participated in the subsidiary topic of the Study of the Comprehensive Therapeutic System of Pancreatic Cancer, 2006BA102A13, a scientific and technological support plan of the 11th Five-Year Plan of the Ministry of Science and Technology.
Reference
1. Wu J, Guo F, Wei J, et al. [Surgicaltreatment for pancreatic neuroendocrine neoplasmas]. Zhejiang da xue xue bao Yixue ban = Journal of Zhejiang University Medical sciences 2016; 45(1): 31-5.
2. Wei J, Liu X, Wu J, et al. Diagnosis andsurgical management of insulinomas in 33 consecutive patients at a singleinstitution. Langenbeck's archives of surgery 2016; 401(7): 1019-25.
3. Tu M, Lu C, Lv N, et al. Vasohibin 2 promoteshuman luminal breast cancer angiogenesis in a non-paracrine manner viatranscriptional activation of fibroblast growth factor 2. Cancer letters 2016;383(2): 272-81.
4. Lu Z, Yin J, Wei J, et al. Small amounts oftissue preserve pancreatic function: Long-term follow-up study ofmiddle-segment preserving pancreatectomy. Medicine 2016; 95(46): e5274.
5. Huo X, Wei J, Liu X, et al. Brunner's glandcyst in combination with gastrointestinal stromal tumor: A case report.Oncology letters 2016; 11(5): 3409-12.
6. Gao W, Dai X, Dai C, et al. Comparison ofpatency rates and clinical impact of different reconstruction methods followingportal/superior mesenteric vein resection during pancreatectomy. Pancreatology: official journal of the International Association of Pancreatology (IAP) [et al] 2016; 16(6): 1113-23.
7. Wei J, Liu X, Wu J, et al. Modified One-layerDuct-to-mucosa Pancreaticojejunostomy Reduces Pancreatic Fistula AfterPancreaticoduodenectomy. International surgery 2015.
8. Wei J, Lin S, Wang C, et al. Glucagonomasyndrome: A case report. Oncology letters 2015; 10(2): 1113-6.
9. Ge Q, Zhou J, Tu M, et al. Nuclearvasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression.Oncology reports 2015; 34(3): 1327-36.
10. Xue X, Zhang Y, Zhi Q, et al.MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumorsby inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Cellcommunication and signaling : CCS 2014; 12: 62.
11. Tu M, Liu X, Han B, et al. Vasohibin2 promotesproliferation in human breast cancer cells via upregulation of fibroblastgrowth factor2 and growth/differentiation factor15 expression. Molecularmedicine reports 2014; 10(2): 663-9.
12. Wei J, Zheng L, Liu S, et al. MiR-196a2rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinesepopulation. Human immunology 2013; 74(9): 1199-205.
13. Tang D, Wang D, Yuan Z, et al. Persistentactivation of pancreatic stellate cells creates a microenvironment favorablefor the malignant behavior of pancreatic ductal adenocarcinoma. Internationaljournal of cancer 2013; 132(5): 993-1003.
14. Sun J, Tu M, Han B, et al. Generation andcharacterization of rabbit polyclonal antibodies against Vasohibin-2 fordetermination of its intracellular localization. International journal ofoncology 2013; 43(1): 255-61.
15. Chen J, Li Q, An Y, et al. CEACAM6 inducesepithelial-mesenchymal transition and mediates invasion and metastasis inpancreatic cancer. International journal of oncology 2013; 43(3): 877-85.
16. Cai B, An Y, Lv N, et al. miRNA-181b increasesthe sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine invitro and in nude mice by targeting BCL-2. Oncology reports 2013; 29(5):1769-76.
17. An Y, Cai B, Chen J, et al. MAP3K10 promotesthe proliferation and decreases the sensitivity of pancreatic cancer cells togemcitabine by upregulating Gli-1 and Gli-2. Cancer letters 2013; 329(2):228-35.
18. Zhang Y, Wei J, Wang H, et al. Epithelialmesenchymal transition correlates with CD24+CD44+ and CD133+ cells inpancreatic cancer. Oncology reports 2012; 27(5): 1599-605.
19. Wang H, Wu J, Zhang Y, et al. Transforminggrowth factor beta-induced epithelial-mesenchymal transition increases cancerstem-like cells in the PANC-1 cell line. Oncology letters 2012; 3(1): 229-33.
20. Tang D, Yuan Z, Xue X, et al. High expressionof Galectin-1 in pancreatic stellate cells plays a role in the development andmaintenance of an immunosuppressive microenvironment in pancreatic cancer.International journal of cancer 2012; 130(10): 2337-48.
21. Chen M, Xue X, Wang F, et al. Expression andpromoter methylation analysis of ATP-binding cassette genes in pancreaticcancer. Oncology reports 2012; 27(1): 265-9.
22. Xue X, Lu Z, Tang D, et al. Galectin-1 secretedby activated stellate cells in pancreatic ductal adenocarcinoma stroma promotesproliferation and invasion of pancreatic cancer cells: an in vitro study on themicroenvironment of pancreatic ductal adenocarcinoma. Pancreas 2011; 40(6):832-9.
23. Wu J, Wei J, Meng K, et al. Identification ofan HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.Immunopharmacology and immunotoxicology 2009; 31(3): 468-76.
24. Wei J, Gao W, Wu J, et al. Dendritic cellsexpressing a combined PADRE/MUC4-derived polyepitope DNA vaccine inducemultiple cytotoxic T-cell responses. Cancer biotherapy &radiopharmaceuticals 2008; 23(1): 121-8.